The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study).
Arantxa Sancho-LópezBelén Ruiz-AntoránTeresa Iglesias HernangómezAlmudena Ramírez-GarcíaIrene Gómez-EstévezJudith Sanabria-CabreraRoser Llop RiusConsuelo PedrósDiana CampodonicoSilvia Jiménez-JorgeAmelia García LuqueLucienne Costa Frossad FrançaEva MontanéAna Aldea-PeronaNieves Téllez LaraMontserrat Bosch FerrerConsuelo Rodriguez JiménezElvira Bonilla-ToyosJulia Sabín MuñozCristina Avendaño-SoláMaria Rosario Blasco Quileznull On Behalf Of The Realhes-Study GroupPublished in: Journal of clinical medicine (2023)
In this study, the incidence and severity of lymphopenia after starting siponimod treatment were higher than those reported in previous clinical trials. Therefore, our results reinforce the need for the closer monitoring of novel MS drugs in clinical practice, as well as larger and longer follow-up studies to properly characterize this risk.